The French-Italian eyewear group EssilorLuxottica reported weak profits for the 2025 financial year on Thursday. At the same time, sales benefited from improved results in all regions.
On average, the company expects solid growth in total sales over the next five years. Adjusted operating profit is expected to grow at approximately the same rate at constant exchange rates.
In the 2025 financial year, the group’s net profit fell by 1.9 percent to 2.32 billion euros. In the previous year it was 2.36 billion euros. Earnings per share fell from EUR 5.13 in the previous year to EUR 4.98. The group’s net profit adjusted for special effects amounted to 3.16 billion euros, compared to 3.12 billion euros in the previous year.
The operating result for the year fell by two percent year-on-year to 3.38 billion euros. At the same time, the adjusted operating result grew by one percent to 4.46 billion euros. The adjusted operating margin for the full year was 16.0 percent at constant exchange rates. That was 70 basis points less than 2024. This was influenced by US tariffs and AI glasses.
Annual sales amounted to 28.5 billion euros, an increase of 7.5 percent compared to the 26.5 billion euros of the previous year. At constant exchange rates, sales increased by 11.2 percent. In the fourth quarter, sales grew by 18.4 percent. The company said the North America, EMEA and Asia Pacific regions achieved double-digit growth in both the most recent quarter and the full year.
The group also announced that the board of directors will recommend the distribution of a dividend of 4.00 euros per share to shareholders at the annual general meeting on April 28th. The dividend payment or the issuance of shares will take place from June 3rd.
Francesco Milleri, Chairman and CEO of EssilorLuxottica, and Paul du Saillant, Deputy CEO, stated: “In an uncertain macroeconomic and geopolitical environment and despite the headwinds from US tariffs, we achieved record results. At the same time, we made bold investments to advance our innovation agenda. We confirm that we are on track with the five-year outlook communicated in March 2022. However, today we are updating it. With the We want to achieve solid sales growth in the next five years, with adjusted operating income growing at approximately the same pace. We are resolutely leading our company on its path to medtech transformation.”
This article was created using digital tools translated.
FashionUnited uses artificial intelligence to speed up the translation of articles and improve the end result. They help us to make FashionUnited’s international reporting quickly and comprehensively accessible to a German-speaking readership. Articles translated using AI-based tools are proofread and carefully edited by our editors before they are published. If you have any questions or comments, please email [email protected]
